Lukas Biomedical Inc. (TPEX:6814)

Market Cap	1.18B +2.2%
Revenue (ttm)	180.32M -16.1%
Net Income	-96.22M
EPS	-2.30
Shares Out	41.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,022
Average Volume	46,480
Open	28.30
Previous Close	28.30
Day's Range	26.80 - 28.30
52-Week Range	16.60 - 32.50
Beta	0.07
RSI	34.65
Earnings Date	Apr 27, 2026

About Lukas Biomedical

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 96
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6814

Financial Performance

In 2024, Lukas Biomedical's revenue was 189.83 million, a decrease of -18.12% compared to the previous year's 231.83 million. Losses were -94.38 million, 99.3% more than in 2023.